Bli medlem
Bli medlem

Du är här

2020-07-14

Promore Pharma is Granted a Patent for ropocamptide in the US

STOCKHOLM, 14 July, 2020 – Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the company was granted a patent in the US for the pharmaceutical formulation of the product candidate ropocamptide (LL-37).

Promore Pharma’s product candidate ropocamptide is being developed to prevent venous leg ulcers (VLU). The company filed a continuation application with the U.S. Patent Office (USPTO) in May 2020 for a previously granted patent, which protects important elements in the formulation of ropocapmtide. The patent has now been formally granted, and it is valid at least until 2034.

“Now we are taking another step in our strategic work to create an extensive intellectual property protection for our innovative prescription drug for treating hard-to-heal ulcers” said Jonas Ekblom, President and CEO of Promore Pharma. “In total, we now have a strong and advanced patent protection for ropocamptide on the world’s largest pharmaceutical market, which of course is of utmost importance when the drug reaches the market”, he continued.

On the traditional pharmaceutical markets, there are an estimated 13-18 million patients with hard-to-heal wound and VLUs constitutes the largest subcategory of these wounds. VLUs represent significant challenges to patients and healthcare systems since they are frequent, costly to manage, recurring, and may persist for months or years. Standard treatment consists of compression bandaging and there are no approved prescription pharmaceuticals for VLUs on the traditional pharmaceutical markets. The cost for treating one VLU episode exceeds 10,000 USD for the healthcare system. The company therefore consider that there is a great need for the candidate drug, both from the perspective of the patients and the healthcare system.

For additional information, please contact


Jonas Ekblom, CEO
Phone: [+46] 736 777 540
Email: jonas.ekblom@promorepharma.com

Jenni Björnulfson, CFO
Phone: [+46] 708 55 38 05
Email: jenni.bjornulfson@promorepharma.com

Promore Pharma’s Certified Adviser is Redeye AB.
Phone: [+46] 8 121 576 90
E-mail: certifiedadviser@redeye.se

Promore Pharma in brief


Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. Ropocamptide (LL-37) is being evaluated in a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

About ropocamptide (LL-37):


Ropocamptide is based on a human antimicrobial peptide, structurally derived from the C-terminal part of human cathelicidin antimicrobial protein 18 (hCAP18), and stimulates the function of several cell types involved in wound healing, including skin keratinocytes and fibroblasts. In the Phase IIa study conducted by Promore Pharma in VLU patients, ropocamptide showed, in the most effective dose, an increase in healing rate of relative wound area reduction of over 75% after one month treatment, suggesting a significantly higher efficacy than what has been reported for any other treatment in chronic wounds. No serious adverse events that were deemed to be caused by the investigational product occurred in the trial. The product candidate can be combined with the standard wound care treatments and can be applied by nurses or potentially by the patient alone. The development of ropocamptide focuses initially on venous leg ulcers but the company sees good potential in developing ropocamptide for also diabetic foot ulcers.

Attachments


Promore Pharma is Granted a Patent for ropocamptide in the US

Författare Promore Pharma

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.